Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00114244 · ClinicalTrials.gov registry record · Phase 2
Sorafenib With or Without Gemcitabine in Treating Patients With Metastatic Pancreatic Cancer
A Phase 2 study of Stage IV Pancreatic Cancer, sponsored by National Cancer Institute (NCI).
- Completed
- Registry status
- Phase 2
- Development phase
- 52
- Enrollment target
- 1
- Study location
NCT00114244 is a Phase 2 study of Stage IV Pancreatic Cancer that has completed, run by National Cancer Institute (NCI). The registered enrollment target is 52 participants, below the 76-participant average among 15 other Stage IV Pancreatic Cancer trials with a reported enrollment target (32% lower). The trial reports 1 study location across 1 state.
The verdict
NCT00114244, a Phase 2 study of Stage IV Pancreatic Cancer, has completed, sponsored by National Cancer Institute (NCI).
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 52 participants
- Enrollment target
- 1
- Study location
Study Summary
This randomized phase II is studying how well giving sorafenib with or without gemcitabine works in treating patients with metastatic pancreatic cancer. Sorafenib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor. Drugs used in chemotherapy, such as gemcitabine, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving sorafenib together with gemcitabine may kill more tumor cells.
Conditions Studied
Interventions
- OTHER laboratory biomarker analysis
- DRUG gemcitabine hydrochloride
- DRUG sorafenib tosylate
Study Locations (1)
California
- City of Hope - Duarte
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 52 participants |
| Start Date | 2004-12 |
| Est. Completion | 2010-09 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00114244
The ClinicalTrials.gov registry entry for NCT00114244 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 52 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 76-participant average among 15 other Stage IV Pancreatic Cancer trials with a reported enrollment target (32% lower). The listed sponsor is National Cancer Institute (NCI), which has 3,257 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Stage IV Pancreatic Cancer appearing as the primary indexed condition, and to 3 interventions - of which laboratory biomarker analysis is the first listed.
NCT00114244 reports 1 study location spanning 1 distinct geographic area - top geographies include California.
Frequently Asked Questions
What is clinical trial NCT00114244 about?
NCT00114244 is a clinical study titled "Sorafenib With or Without Gemcitabine in Treating Patients With Metastatic Pancreatic Cancer". This randomized phase II is studying how well giving sorafenib with or without gemcitabine works in treating patients with metastatic pancreatic cancer. Sorafenib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor. Drugs ...
What is the current status of trial NCT00114244?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 52 participants. The study started on 2004-12. Estimated completion is 2010-09.
What conditions does trial NCT00114244 study?
This clinical trial studies the following conditions: Stage IV Pancreatic Cancer.
What interventions are being tested in trial NCT00114244?
The interventions under investigation include: laboratory biomarker analysis (OTHER), gemcitabine hydrochloride (DRUG), sorafenib tosylate (DRUG).
Who is sponsoring clinical trial NCT00114244?
This trial is sponsored by National Cancer Institute (NCI), which has 3,257 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00114244 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Stage IV Pancreatic Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Ceralasertib (AZD6738) Alone and in Combination With Olaparib or Durvalumab in Patients With Solid Tumors
RECRUITING · Phase 2
-
Gamma Secretase Inhibitor RO4929097 in Previously Treated Metastatic Pancreas Cancer
COMPLETED · Phase 2
-
Triapine as First-Line or Second-Line Therapy in Treating Patients With Locally Advanced or Metastatic Cancer of the Pancreas
COMPLETED · Phase 2
-
Docetaxel and Flavopiridol in Treating Patients With Refractory Metastatic Pancreatic Cancer
COMPLETED · Phase 2
-
Paclitaxel and Bryostatin 1 in Treating Patients With Advanced Pancreatic Cancer
COMPLETED · Phase 2
-
CCI-779 in Treating Patients With Locally Advanced or Metastatic Pancreatic Cancer
COMPLETED · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.